TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Tara Bancroft, Ph.D.

Vice President

Tara Bancroft

Tara Bancroft, Ph.D. is a Vice President and senior equity research analyst on the biotechnology team at TD Cowen. Dr. Bancroft has over five years of equity research experience covering large-, mid-, and small-cap biotechnology stocks.

Prior to joining TD Cowen, Dr. Bancroft was an AVP at Piper Sandler (previously Piper Jaffray) for three years. Prior to Piper Sandler, Dr. Bancroft spent over four years as a postdoctoral researcher first at the La Jolla Institute for Immunology in San Diego where she identified optimized antigen epitopes for a re-formulated pertussis vaccine that went on to be published in Cellular Immunology and others. She then completed a postdoc at Fred Hutch in Seattle, where she discovered B-cell precursors to protective anti-HIV antibodies for the purpose of HIV vaccine design (which was published in JEM and others).

She received her Ph.D. from Yale University where she focused on discovering novel mechanisms involved in vascular injury and inflammation, resulting in numerous primary publications. She also completed a BS in biology at SUNY Buffalo, where she worked full-time in an oncology lab (with published work in JCP) and at an HIV clinical trial center.

Get In Touch

Start a conversation with Tara Bancroft, Ph.D.


    Explore related thought leadership, reports, coverage and insights for Tara Bancroft, Ph.D..

    Medical researcher conducting pharmaceutical research in a lab. Representing innovation in biotech and oncology, specifically in anti body drug conjugates (ADSs).
    Ahead of the Curve®

    5th Annual Investor Primer on Antibody Drug Conjugates

    A lightbulb planted in soil with a sprout growing from inside it representing our best ESG investment ideas for 2023.

    Best ESG Investment Ideas for 2023

    Close up of a microscope studying a blood sample representing a recent report on radiopharmaceuticals and treating cancer.
    Ahead of the Curve®

    A Primer On The Next Generation Of Radiopharmaceuticals